Patient Services

With almost 20 years of experience, Case Managers in Genzyme's Patient and Product Services Department provide free and voluntary care coordination, support and services to individuals living with Gaucher disease who reside in the United States. Genzyme Case Managers are healthcare professionals employed by Genzyme committed to helping individuals connect with all resources available to them. 

Whether you have just been diagnosed with Type 1 Gaucher disease and are exploring treatment with Cerezyme with your doctor or you are considering resuming treatment, Genzyme Case Managers are available to assess your unique situation and answer any questions you may have, including helping you understand your insurance options for treatment with Cerezyme.  Our confidential services are offered at no cost to you and are completely voluntary.

Your Call, Our Commitment 

A Genzyme Case Manager is only a phone call away from answering your questions and working with you to help address your needs.

1-800-745-4447, Option 3

Monday through Friday, 8:00 AM to 6:00 PM EST

Spanish-speaking Case Managers are available, as well as interpreters for other languages.

Information you provide will always be kept confidential. Genzyme offers all Care Coordination services in compliance with patient privacy regulations (HIPAA).

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).